-
EP2729144
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP Citations: EP2729144
| Cited in | International search | Type: | Patent literature | Publication No.: | WO2007139951
[X] (SYNTA PHARMACEUTICALS CORP [US], et al) [X] 1,2,9,21,22 * See claims 220-259 and see compound at page 206, entry 226: The relevant compounds and their use for the treatment of cancers expressing the NPM-ALK fusion protein: *; | Type: | Patent literature | Publication No.: | WO2008153730
[A] (SYNTA PHARMACEUTICALS CORP [US], et al) [A] 1-16,21-23 * See claims and see compound at page 191, entry 226: The relevant compounds and their use for the treatment of cancers expressing the c-met fusion protein *; | Type: | Patent literature | Publication No.: | WO2009102446
[Y] (BRIGHAM & WOMENS HOSPITAL [US], et al) [Y] 1-16,21-23 * See claims 1, 48, 55: assay for identifying EML4-ALK mutations, and methods of treatment of cancers associated with EML4-ALK mutation using, inter alia crizotinib *; | Type: | Patent literature | Publication No.: | WO2011049946
[Y] (SYNTA PHARMACEUTICALS CORP [US], et al) [Y] 1-16,21-23* See claims: the relevant compounds to treat NSCLC cancer, in combination with other agents *; | Type: | Non-patent literature | Publication information: | [XO] - Geoffrey Shapiro, "Phase II study of the Hsp90 inhibitor ganetespib as monotherapy in patients with advanced NSCLC", (201106), INTERNET-U-Tube, URL: http://www.youtube.com/watch?v=UX8fEZbF1bk, (20120913) [XO] 1-5,7,8 * See the presentation from Dr Shapiro, registered at the 2011 ASCO meeting (June 3 - 7, 2011) which was uploaded in the internet on 27.06.2011, describing the positive results of the clinical study in which the compound ganetespib was administered to EML4-Alk positive NSCLC patients and the use of such compound for treating patients resistant to crizotinib * | Type: | Non-patent literature | Publication information: | [XP] - Reichert et al, "Ganetespib: An effective strategy to overcomecrizotinib resistance in ALK-driven cancers", (20120421), INTERNET, URL: http://www.syntapharma.com/Documents/Ganetespib_ALK_Euro_IASLC_2012_Poster.pdf, (20120914), XP002683507 [XP] 1-8,12,13,16,21-23 * See abstract: Ganetespib overcomes crizotinib resistance NSCLC cancer patients expressiong the EML4-Alk mutation. Ganetespib also produces synergistic activity with crizotinib * | Type: | Non-patent literature | Publication information: | [X] - YING WEIWEN ET AL, "Preclinical Evaluation of A Potent 2(nd) Generation Small-Molecule Hsp90 Inhibitor STA-9090 In Hematological Cell Lines", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 116, no. 21, ISSN 0006-4971, (20101101), page 1194, (20101119), XP009162837 [X] 1,2,9,21,22 * See abstract: STA-9090 (ganetespib), the preferred compounds of the invention has utility in the treatment of NSCLC and is able to destabilise NPM-ALK and other oncogenic kinases overexpressed in mutated hematologic cancers * | Type: | Non-patent literature | Publication information: | [Y] - RYOHEI KATAYAMA ET AL, "Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 108, no. 18, doi:10.1073/PNAS.1019559108, ISSN 0027-8424, (20110503), pages 7535 - 7540, (20110418), XP002672743 [Y] 1-16,21-23 * See abstract, results and discussion: crizotinib resistance in NSCLC cancer is associated with amplification of the EML4-ALK gene and can be overcome with Alk inhibitors and Hsp90 inhibitors (see pages 3-4 and conclusions at page 6) * | DOI: | http://dx.doi.org/10.1073/pnas.1019559108 | Type: | Non-patent literature | Publication information: | [Y] - NWIZU T ET AL, "CRIZOTINIB ALK/Met inhibitor Oncolytic", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, (20110201), vol. 36, no. 2, doi:10.1358/DOF.2011.36.2.1584112, ISSN 0377-8282, pages 91 - 99, XP009154039 [Y] 1-16,21-23 * See summary, clinical trials and table 1: crizotinib is active in NSCLC cancers with EML4-ALK gene rearrangements and is also active against tyrosine-protein kinase Met * | DOI: | http://dx.doi.org/10.1358/dof.2011.36.2.1584112 | Cited in | Examination | Type: | Non-patent literature | Publication information: | - WHO, "International Nonproprietary Names for Pharmaceutical Substances (INN)", (20110630), URL: http://www.who.int/medicines/publications/druginformation/innlists/PL105.pdf?ua=1 | Type: | Non-patent literature | Publication information: | - DAVID A PROIA ET AL, "Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, (20110414), vol. 6, no. 4, doi:10.1371/JOURNAL.PONE.0018552, ISSN 1932-6203, pages E18552 - 1, XP002674768 | DOI: | http://dx.doi.org/10.1371/journal.pone.0018552 | Cited in | by applicant | Type: | Patent literature | Publication No.: | US3536809
| Type: | Patent literature | Publication No.: | US3598123
| Type: | Patent literature | Publication No.: | CH542802
| Type: | Patent literature | Publication No.: | US3845770
| Type: | Patent literature | Publication No.: | US3916899
| Type: | Patent literature | Publication No.: | US4008719
| Type: | Patent literature | Publication No.: | US5059595
| Type: | Patent literature | Publication No.: | US5073543
| Type: | Patent literature | Publication No.: | US5120548
| Type: | Patent literature | Publication No.: | US5354556
| Type: | Patent literature | Publication No.: | US5529925
| Type: | Patent literature | Publication No.: | US5591767
| Type: | Patent literature | Publication No.: | US5639476
| Type: | Patent literature | Publication No.: | US5674533
| Type: | Patent literature | Publication No.: | US5733566
| Type: | Patent literature | Publication No.: | US5770421
| Type: | Patent literature | Publication No.: | US2006167070
| Type: | Patent literature | Publication No.: | WO2009023211
| Type: | Patent literature | Publication No.: | US7700339
| Type: | Patent literature | Publication No.: | US2011110923
| Type: | Non-patent literature | Publication information: | - NATURE REVIEWS CLINICAL ONCOLOGY, (201205), vol. 9, pages 268 - 277 | Type: | Non-patent literature | Publication information: | - BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY, (1995), vol. 172-178, pages 949 - 982 | Type: | Non-patent literature | Publication information: | - PALMER ET AL., BIOCHEM. J., (2009), pages 345 - 361 | Type: | Non-patent literature | Publication information: | - KOIVUNEN ET AL., CLIN. CAN. RES., (2008), vol. 14, pages 4275 - 4283 | Type: | Non-patent literature | Publication information: | - ANDERSON, EXPERT REV. MOL. DIAGN., (2011), vol. 11, no. 6, pages 635 - 642 | Type: | Non-patent literature | Publication information: | - PINTO ET AL., CANCER GENETICS, (2011), vol. 204, pages 439 - 446 | Type: | Non-patent literature | Publication information: | - REKHTMAN ET AL., CLIN CANCER RES, (2012), vol. 18, pages 1167 - 1176 | Type: | Non-patent literature | Publication information: | - MASSARELLI ET AL., CLIN CANCER RES, (2007), vol. 13, pages 2890 - 2896 | Type: | Non-patent literature | Publication information: | - LAMY ET AL., MODERN PATHOLOGY, (2011), vol. 24, pages 1090 - 1100 | Type: | Non-patent literature | Publication information: | - BALSCHUN ET AL., EXPERT REV. MOL. DIAGN., (2011), vol. 11, no. 8, pages 799 - 802 | Type: | Non-patent literature | Publication information: | - VAKIANI ET AL., J PATHOL, (2011), vol. 223, pages 219 - 229 | Type: | Non-patent literature | Publication information: | - OKUDELA ET AL., PATHOLOGY INTERNATIONAL, (2010), vol. 60, pages 651 - 660 | Type: | Non-patent literature | Publication information: | - JOHN ET AL., ONCOGENE, (2009), vol. 28, pages S14 - S23 | Type: | Non-patent literature | Publication information: | - QIAN ET AL., CANCER RESEARCH, (2002), vol. 62, pages 589 - 596 | Type: | Non-patent literature | Publication information: | - MA ET AL., CANCER AND METASTASIS REVIEWS, (2003), vol. 22, pages 309 - 325 | Type: | Non-patent literature | Publication information: | - CHRISTENSEN ET AL., CANCER RESEARCH, (2003), vol. 63, pages 7345 - 7355 | Type: | Non-patent literature | Publication information: | - BERTHOU ET AL., ONCOGENE, (2004), vol. 23, pages 5387 - 5393 |